Care Health Insurance (Religare) Unlisted Shares

Care Health Insurance (Religare) Unlisted Shares

IRDAI puts Care Health Insurance on notice over ESOPs to Saluja

The Ecoonomic Times

2 min read

IRDAI Issues Notice to Care Health Insurance Over Unauthorized ESOPs to Chairperson Saluja.

Expert Analysis: 

  • Regulatory Action: India's insurance regulator IRDAI issued a show cause notice to Care Health Insurance, a Religare Enterprises subsidiary, over stock options granted to Religare chairperson Rashmi Saluja.

  • Board Conflict: The Religare board and Dabur's Burman family are in a protracted control battle, with the Burmans accusing the board of unlawfully granting stock options to Rashmi Saluja and alleging non-compliance with IRDAI regulations.

  • IRDAI Directive: Stock options were issued to Rashmi Saluja despite IRDAI's May 2022 directive not approving Care from granting ESOPs to her as a non-executive director.

  • ESOP Value: Despite IRDAI guidelines capping non-executive director payments at ₹10 lakh per year, Care issued ESOPs to Rashmi Saluja as a Religare Enterprises employee, which IRDAI views as defiance of its directives.

  • Regulatory Consequences: The company faces a show cause notice demanding justification for avoiding penalties and proceedings under the Insurance Act and IRDAI Act 1999.

  • Investigation into Stock Options: ET reported that IRDAI is investigating the issuance of stock options worth ₹250 crore to Rashmi Saluja by Care Health, representing approximately 2.5% of the insurer's unlisted shareholding.

  • Discrepancy in Share Pricing: Proxy advisory firm InGovern reported that Care Health Insurance issued stock options at an exercise price of ₹45.32 per share in January 2022, while the rights issue that year was priced at ₹110 per share.

  • Burman Family Allegations: The Burman family, the largest shareholder of Religare Enterprises claims 22.7 million options were issued illegally and sought to cancel these stock options.

  • SAT Compliance Directive: The Securities Appellate Tribunal (SAT) directed Religare Enterprises to apply for an open offer and change in control by July 22, following orders from the Securities and Exchange Board of India (Sebi) issued on June 19, 2024.

Takeaways
  • Regulatory Challenge:

    • Care Health Insurance is scrutinized for issuing ₹250 crore in stock options to Rashmi Saluja against IRDAI's directive.

  • Governance Conflict:

    • The Burman family, Religare's major shareholders, alleges that 22.7 million options were illicitly issued and demands their cancellation.

  • Compliance Mandate:

    • The Securities Appellate Tribunal has ordered Religare Enterprises to follow SEBI's directions on open offer and control change by July 22.

  • Governance and Compliance Risks:

    • This situation highlights significant governance and regulatory adherence issues within Care Health Insurance.

Invest in the Future
Act now and capitalize on the potential growth of this unlisted share

Precize Daily Pulse

The latest news in the world of Unlisted Shares, summarised by our experts.

The next generation of asset classes in India

Resources

Our Office

Office No. 1219, The Summit Business Park, Andheri Kurla Road, Andheri East, Mumbai, Maharashtra - 400093

Find us on Google

support@precize.in

+91 7738336457

All trademarks and logos or registered trademarks and logos found on this Site or mentioned herein belong to their respective owners and are solely used for informational and educational purposes.

The material presented in this advertisement is for informational purposes only and should not be construed as investment advice or investment availability. It is not a recommendation of, or an offer to sell or solicitation of an offer to buy, any particular unlisted share, security, strategy, or investment product. Investing in the private market and securities involves risks, including the potential loss of money, and past performance does not guarantee future results. Market trends, data interpretations, graph projections are provided for informational and illustrative purposes and may not reflect actual future performance. Nothing on this website should be construed as personalized investment advice or should not be treated as legal, financial, or any other form of advice. Precize is not liable for financial or any other form of loss incurred by the user or any affiliated party based on information provided herein.

Precize is neither a stock exchange nor does it intend to get recognized as a stock exchange under the Securities Contracts Regulation Act, 1956. Precize is not authorized by the capital markets regulator to solicit investments. The securities traded on these platforms are not traded on any regulated exchange.

The website will be updated regularly.

Copyright © 2026 - Precize - All Rights Reserved